摘要
目的分析他莫昔芬(tamoxifan,TAM)联合小剂量甲地孕酮(megestrol acetate,MA)对子宫内膜癌的临床疗效。方法将本院2020年1月—2022年12月收治的76例子宫内膜癌患者随机分为A组(使用小剂量MA治疗)与B组(使用TAM+小剂量MA治疗),每组38例。比较两组疗效、血清肿瘤标志物与炎症因子水平及不良反应发生情况。结果B组治疗总有效率优于A组,差异有统计学意义(P<0.05)。治疗前,两组血清癌胚抗原、糖类抗原125(CA12-5)、类胰岛素一号生长因子、甲壳质酶蛋白水平对比差异无统计学意义(P>0.05);治疗后,B组这4项因子水平均低于A组,差异有统计学意义(P<0.05)。A、B组不良反应总发生率分对比差异无统计学意义(P>0.05)。结论TAM联合小剂量MA治疗子宫内膜癌,不仅可以显著提升疗效,还有助于调节患者体内肿瘤标志物水平,且不会增加过多不良反应,应用价值较高。
Objective To analyze clinical effect of tamoxifen(TAM)combined with low-dose megestrol acetate(MA)in treatment of endometrial cancer.Methods The paper chose 76 patients with endometrial cancer admitted to our hospital from January 2020 to December 2022,and divided them into group A(treated with low-dose megestrol acetate)and group B(treated with TAM+low-dose megestrol acetate)randomly,with 38 cases in each group.Effect,serum tumor markers and inflammatory factor levels,and incidence of adverse reactions were compared between two groups.Results Total effective rate of treatment in Group B was better than group A,difference was statistically significant(P<0.05).Before treatment,there was no difference in levels of serum carcinoembryonic antigen,CA12-5,insulin-like growth factor 1,and chitinase protein between two groups(P>0.05).After treatment,levels of these four factors in group B were lower than group A,difference was statistically significant(P<0.05).There was no statistically significant difference in total incidence of adverse reactions between group A and B(P>0.05).Conclusion Combination of tamoxifen and low-dose megestrol acetate can significantly improve curative effect,regulate levels of tumor markers of endometrial cancer patients,without increasing many adverse reactions,which has high application value.
作者
杨雪峰
高夏
YANG Xuefeng;GAO Xia(Yantai Qixia City People's Hospital,Yantai,Shandong,265300)
出处
《智慧健康》
2024年第8期73-76,共4页
Smart Healthcare
关键词
子宫内膜癌
他莫昔芬
小剂量
甲地孕酮
血清肿瘤标志物
炎症因子
不良反应
Endometrial cancer
Tamoxifen
Low dose
Medroxyprogesterone
Serum tumor markers
Inflammatory factors
Adverse reactions
